UK Value Investing Opportunities: Why Fevertree Drinks and Its Peers May Be Trading Below Fair Value in 2026

The UK beverage sector has long been a fertile ground for value investors, but 2026 may present a unique inflection point. Fevertree Drinks PLC (FEVR.L), a leader in premium non-alcoholic beverages, and its peers are trading at significant discounts to intrinsic value, according to discounted cash flow (DCF) analysis and earnings growth projections. This article examines why these companies may represent compelling opportunities for investors seeking undervalued assets in a sector poised for structural transformation.

Fevertree Drinks: A Case of Mispriced Potential

Fevertree Drinks has demonstrated a remarkable turnaround in earnings growth. While the company's earnings declined at an average annual rate of -20.5% over the past five years, it recently accelerated to a 15.1% increase in 2024, outpacing both its historical trend and the broader beverage industry's 11.6% growth. This momentum is underpinned by a strategic shift toward non-tonic products, which now account for 45% of group revenue. These products grew from 10% of sales in 2019 to ~30% by 2025, reflecting a diversification that has driven margin expansion. Adjusted EBITDA surged 66% to £50.7 million in FY2024, with gross margins expanding by 540 basis points to 37.5%.

Despite these improvements, Fevertree's stock trades at a 47.7% discount to its estimated fair value of £15.82, based on a DCF model. This undervaluation appears to stem from short-term challenges, such as a 6% decline in UK revenue in H1 2025 due to a weak on-trade environment. However, the company's projected earnings growth of over 20% annually and a net margin improvement from 4.23% in 2021 to 9.7% in 2025 suggest a strong earnings trajectory.

DCF Analysis: A Framework for Valuation

To assess Fevertree's intrinsic value, we apply a DCF model using industry-specific parameters. The UK beverage sector's weighted average cost of capital (WACC) is estimated at 7.04% for soft drinks, a figure derived from U.S. sector benchmarks and adjusted for UK-specific risks such as inflationary pressures and labor costs. Fevertree's free cash flow volatility- exemplified by a 1,288.46% surge in one year and a 90.97% decline in another-introduces uncertainty, but its recent Q2 2025 free cash flow of £11.90 million and a cumulative £44.5 million by June 30, 2025, provide a baseline for projections. Assuming a 20% annual earnings growth rate and a 7.04% discount rate, Fevertree's intrinsic value aligns closely with the £15.82 fair value estimate, reinforcing the case for undervaluation.

Peer Comparisons: Britvic and AG Barr in Context

Fevertree's peers, such as Britvic PLC and AG Barr, offer further insights. Britvic, now delisted after its acquisition by Carlsberg, reported a free cash flow of £85.5 million in 2024, significantly higher than Fevertree's £44.5 million by mid-2025. However, Britvic's adjusted EPS growth of 13.9% in 2024 lags behind Fevertree's projected 20%+ earnings growth. AG Barr, another competitor, saw a 16.7% increase in EPS in 2024, but its free cash flow performance was mixed, with a -51.8% decline in 2023. These comparisons highlight Fevertree's superior earnings momentum despite its smaller scale.

Industry Tailwinds: Health Trends and Premiumization

The broader beverage industry is undergoing a structural shift toward health-conscious and functional products. The non-alcoholic beverage market is projected to reach $3.4 trillion globally by 2034, while the functional beverage segment-encompassing nutraceuticals and wellness-focused drinks-has grown by 54% since 2020. Fevertree's focus on premium, low-alcohol, and non-alcoholic beverages positions it to capitalize on these trends. Additionally, the "sober curious" movement has driven a 9% increase in non-alcoholic beer volume in 2024, a demographic shift that aligns with Fevertree's product portfolio.

Risks and Mitigants

Critics may argue that Fevertree's heavy reliance on the UK market (which accounts for most of its revenue) exposes it to regional economic risks. However, the company's recent expansion into non-tonic products and its strong brand equity in premium beverages mitigate this concern. Furthermore, the beverage industry's projected CAGR of 4.16% from 2025 to 2030 suggests a resilient long-term outlook, even in a challenging macroeconomic environment.

Conclusion: A Compelling Value Proposition

Fevertree Drinks and its peers represent compelling value opportunities in 2026. Fevertree's combination of strong earnings growth, margin expansion, and favorable industry tailwinds, coupled with a significant discount to intrinsic value, makes it an attractive candidate for DCF-driven investors. While free cash flow volatility and UK market exposure warrant caution, the company's strategic alignment with health trends and its projected 20%+ earnings growth justify a bullish outlook. For investors with a long-term horizon, Fevertree's current valuation offers a margin of safety in a sector poised for reinvention.